Skip to main content Accessibility help
  • Print publication year: 2010
  • Online publication date: December 2010

10 - Mature T-cell and natural-killer cell leukemias

from Part 2 - Hematological malignancies



Mature T-cell and natural-killer cell (NK-cell) leukemias consist of T-cell prolymphocytic leukemia (T-PLL), T-cell large granular lymphocytic leukemia (T-LGL), chronic lymphoproliferative disorder of NK-cells (NK-CLPN), adult T-cell leukemia/lymphoma (ATLL) and Sézary syndrome (SS). These disorders comprise a relatively uncommon group of neoplasms which, with the exception of T-PLL, lack a recurrent cytogenetic “marker.” Consequently, the successful diagnosis of a mature T/NK-cell leukemia requires the integration of a variety of parameters.

The evaluation of a patient for a possible T/NK-cell chronic lymphoproliferative disorder is generally triggered by a symptom. Some of these symptoms are non-specific such as fatigue, secondary infection and bleeding, all of which are linked to underlying hematopoietic compromise. Other symptoms are somewhat more disease-specific including skin manifestations in SS, and less often in ATLL (> 50%) and T-PLL (20%). Some patients with mature T/NK-cell leukemias are severely symptomatic (especially patients with T-PLL and ATLL), while other patients may be entirely asymptomatic (NK-CLPN and T-LGL). In these asymptomatic patients, the work-up is generally triggered by an abnormal blood count.

The blood count is typically the starting point for a more “refined” diagnostic work-up. The blood count parameters, including morphological review and differential cell count, highlight an absolute lymphocytosis in patients with T/NK leukemias, or at least an increase in the absolute number of large granular lymphocytes (LGLs) in patients with either T-LGL or NK-CLPN. The white blood cell count (WBC) is typically markedly elevated in patients with T-PLL and at least moderately elevated in patients with ATLL and SS. The WBC is much more variable in patients with T-LGL or NK-CLPN, but there is an absolute increase in LGLs even in cases in which the absolute lymphocyte count is within the normal range.

Catovsky, D, Ralfkiaer, E. T-cell prolymphocytic leukaemia. In Swerdlow, SH, Campo, E, Harris, Net al. (eds.). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 270–1.
Chan, J, Ralfkiaer, E, Ko, Y-H. Aggressive NK-cell leukaemia. In Swerdlow, SH, Campo, E, Harris, NLet al. (eds.), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 276–77.
Jaffe, E, Stein, H, Campo, E, Pileri, S, Swerdlow, S. Introduction and overview of the classification of the lymphoid neoplasms. In Swerdlow, SH, Campo, E, Harris, NLet al. (eds.), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 158–66.
Ohshima, A, Jaffe, ES, Kikuchi, M.Adult T-cell leukaemia/lymphoma. In Swerdlow, SH, Campo, E, Harris, NLet al. (eds.), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 281.
Ralfkiaer, E. Sézary syndrome. In Swerdlow, SH, Campo, E, Harris, NLet al. (eds.), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 299.
Foucar, K.Mature T-cell leukemias including T-prolymphocytic leukemia, adult T-cell leukemia/lymphoma, and Sezary syndrome. Am J Clin Pathol 2007;127(4):496–510.
Villamor, N, Chan, W, Foucar, K. Chronic lymphoproliferative disorders of NK cells. In Swerdlow, S, Campo, E, Harris, Net al. (eds.), WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. Lyon: IARC Press; 2008, 274–75.
Dearden, CE, Matutes, E, Cazin, Bet al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood 2001;98(6):1721–6.
Dungarwalla, M, Matutes, E, Dearden, CE. Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol 2008;80(6):469–76.
Jiang, L, Yuan, CM, Hubacheck, Jet al. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy. Br J Haematol 2009;145(2):173–9.
Herling, M, Khoury, JD, Washington, LTet al. A systematic approach to diagnosis of mature T-cell leukemias reveals heterogeneity among WHO categories. Blood 2004;104(2):328–35.
Maljaei, SH, Brito-Babapulle, V, Hiorns, LR, Catovsky, D. Abnormalities of chromosomes 8, 11, 14, and X in T-prolymphocytic leukemia studied by fluorescence in situ hybridization. Cancer Genet Cytogenet 1998;103(2):110–16.
Khot, A, Dearden, C.T-cell prolymphocytic leukemia. Expert Rev Anticancer Ther 2009;9(3):365–71.
Alekshun, TJ, Sokol, L. Diseases of large granular lymphocytes. Cancer Control 2007;14(2):141–50.
Burks, EJ, Loughran, TPPerspectives in the treatment of LGL leukemia. Leuk Res 2005;29(2):123–5.
Mohan, SR, Maciejewski, JP. Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Curr Opin Hematol 2009;16(1):27–34.
Zhang, R, Shah, MV, Yang, Jet al. Network model of survival signaling in large granular lymphocyte leukemia. Proc Natl Acad Sci USA 2008;105(42):16308–13.
Sokol, L, Loughran, TPLarge granular lymphocyte leukemia. Oncologist 2006;11(3):263–73.
Choi, YL, Makishima, H, Ohashi, Jet al. DNA microarray analysis of natural killer cell-type lymphoproliferative disease of granular lymphocytes with purified CD3–CD56+ fractions. Leukemia 2004;18(3):556–65.
Epling-Burnette, PK, Painter, JS, Chaurasia, Pet al. Dysregulated NK receptor expression in patients with lymphoproliferative disease of granular lymphocytes. Blood 2004;103(9):3431–9.
Foucar, K, Matutes, E, Dearden, C, Catovsky, D.Chronic T-cell and natural killer cell leukemias. In Armitage, JCB, Dalla-Favera, R, Harris, NL, Mauch, P (eds.), Non-Hodgkin Lymphoma. Lippincott Williams & Wilkins; 2009.
Lima, M, Almeida, J, Montero, AGet al. Clinicobiological, immunophenotypic, and molecular characteristics of monoclonal CD56−/+dim chronic natural killer cell large granular lymphocytosis. Am J Pathol 2004;165(4):1117–27.
Scquizzato, E, Teramo, A, Miorin, Met al. Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia 2007;21(5):1060–9.
Verheyden, S, Bernier, M, Demanet, C. Identification of natural killer cell receptor phenotypes associated with leukemia. Leukemia 2004;18(12):2002–7.
Zambello, R, Falco, M, Della Chiesa, Met al. Expression and function of KIR and natural cytotoxicity receptors in NK-type lymphoproliferative diseases of granular lymphocytes. Blood 2003;102(5):1797–805.
Rabbani, GR, Phyliky, RL, Tefferi, A. A long-term study of patients with chronic natural killer cell lymphocytosis. Br J Haematol 1999;106(4):960–6.
Yokote, T, Akioka, T, Oka, Set al. Flow cytometric immunophenotyping of adult T-cell leukemia/lymphoma using CD3 gating. Am J Clin Pathol 2005;124(2):199–204.
Liu, TY, Chen, CY, Tien, HF, Lin, CW. Loss of CD7, independent of galectin-3 expression, implies a worse prognosis in adult T-cell leukaemia/lymphoma. Histopathology 2009;54(2):214–20.
Nicot, C.Current views in HTLV-I-associated adult T-cell leukemia/lymphoma. Am J Hematol 2005;78(3):232–9.
Nadella, MV, Dirksen, WP, Nadella, KSet al. Transcriptional regulation of parathyroid hormone-related protein promoter P2 by NF-kappaB in adult T-cell leukemia/lymphoma. Leukemia 2007;21(8):1752–62.
Uchiyama, T.Adult T-cell leukemia. Blood Rev 1988;2(4):232–8.
Uchiyama, T, Yodoi, J, Sagawa, K, Takatsuki, K, Uchino, H. Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977;50(3):481–92.
Kamihira, S, Sugahara, K, Tsuruda, Ket al. Proviral status of HTLV-1 integrated into the host genomic DNA of adult T-cell leukemia cells. Clin Lab Haematol 2005;27(4):235–41.
Kchour, G, Tarhini, M, Kooshyar, MMet al. Phase 2 study of the efficacy and safety of the combination of arsenic trioxide, interferon alpha, and zidovudine in newly diagnosed chronic adult T-cell leukemia/lymphoma (ATL). Blood 2009;113(26):6528–32. Syndrome(MFSS-1).
Olsen, E, Vonderheid, E, Pimpinelli, Net al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110(6):1713–22.
Bahler, DW, Hartung, L, Hill, S, Bowen, GM, Vonderheid, EC. CD158k/KIR3DL2 is a useful marker for identifying neoplastic T-cells in Sezary syndrome by flow cytometry. Cytometry B Clin Cytom 2008;74(3):156–62.
Morice, WG, Katzmann, JA, Pittelkow, MRet al. A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sezary syndrome. Am J Clin Pathol 2006;125(3):364–74.
Vonderheid, EC, Bernengo, MG, Burg, Get al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46(1):95–106.
Kim, YH, Duvic, M, Obitz, Eet al. Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood 2007;109(11):4655–62.
Ure, UB, Ar, MC, Salihoglu, Aet al. Alemtuzumab in Sezary syndrome: efficient but not innocent. Eur J Dermatol 2007;17(6):525–9.